The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease by Kvartsberg, H et al.
Vol.:(0123456789) 
Acta Neuropathologica 
https://doi.org/10.1007/s00401-018-1910-3
ORIGINAL PAPER
The intact postsynaptic protein neurogranin is reduced in brain tissue 
from patients with familial and sporadic Alzheimer’s disease
Hlin Kvartsberg1  · Tammaryn Lashley2,3 · Christina E. Murray2,4 · Gunnar Brinkmalm1,5 · Nicholas C. Cullen1 · 
Kina Höglund1,5,6 · Henrik Zetterberg1,3,4,5 · Kaj Blennow1,5 · Erik Portelius1,5
Received: 6 August 2018 / Revised: 14 September 2018 / Accepted: 14 September 2018 
© The Author(s) 2018
Abstract
Synaptic degeneration and neuronal loss are early events in Alzheimer’s disease (AD), occurring long before symptom 
onset, thus making synaptic biomarkers relevant for enabling early diagnosis. The postsynaptic protein neurogranin (Ng) 
is a cerebrospinal fluid (CSF) biomarker for AD, also in the prodromal phase. Here we tested the hypothesis that during 
AD neurodegeneration, processing of full-length Ng into endogenous peptides in the brain is increased. We characterized 
Ng in post-mortem brain tissue and investigated the levels of endogenous Ng peptides in relation to full-length protein in 
brain tissue of patients with sporadic (sAD) and familial Alzheimer’s disease (fAD), healthy controls and individuals who 
were cognitively unaffected but amyloid-positive (CU-AP) in two different brain regions. Brain tissue from parietal cortex 
[sAD (n = 10) and age-matched controls (n = 10)] and temporal cortex [sAD (n = 9), fAD (n = 10), CU-AP (n = 13) and 
controls (n = 9)] were included and all the samples were analyzed by three different methods. Using high-resolution mass 
spectrometry, 39 endogenous Ng peptides were identified while full-length Ng was found to be modified including disulfide 
bridges or glutathione. In sAD parietal cortex, the ratio of peptide-to-total full-length Ng was significantly increased for 
eight endogenous Ng peptides compared to controls. In the temporal cortex, several of the peptide-to-total full-length Ng 
ratios were increased in both sAD and fAD cases compared to controls and CU-AP. This finding was confirmed by western 
blot, which mainly detects full-length Ng, and enzyme-linked immunosorbent assay, most likely detecting a mix of peptides 
and full-length Ng. In addition, Ng was significantly associated with the degree of amyloid and tau pathology. These results 
suggest that processing of Ng into peptides is increased in AD brain tissue, which may reflect the ongoing synaptic degen-
eration, and which is also mirrored as increased levels of Ng peptides in CSF.
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Introduction
Alzheimer’s disease (AD) is the most common form of 
dementia, affecting tens of millions of people worldwide and 
with numbers increasing each year [1]. AD is a neurodegen-
erative disorder characterized by certain neuropathological Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s0040 1-018-1910-3) contains 
supplementary material, which is available to authorized users.
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hallmarks in the brain including extracellular plaques con-
sisting of amyloid β (Aβ) peptides and intracellular neu-
rofibrillary tangles composed of hyperphosphorylated tau 
(p-tau) protein [9]. Most AD patients have no known cause 
and are termed sporadic (sAD), but around 1% are due to 
autosomal dominant mutations in genes related to amyloid 
metabolism, e.g., APP, PSEN1 and PSEN2, causing the 
hereditary form called familial AD (fAD) [6, 13, 55]. In 
contrast to sporadic AD, which usually presents after the age 
of 65, the onset of fAD is generally much earlier.
Even at early stages of the disease, dysfunction and loss 
of synapses are directly linked to cognitive symptoms such 
as memory disturbances and are thought to occur earlier than 
neuronal loss [18]. In fact, the degree of dementia has been 
found to be more associated with synaptic loss compared to 
amyloid plaques and tangles [8, 16, 37, 52, 58]. In addition, 
studies using immunohistochemistry and immunoelectron-
microscopy also suggest that synaptic loss occur without 
clear relation to plaque pathology [8, 36]. Synaptic loss is 
especially pronounced in certain areas of the brain such as 
the hippocampus [52, 53]. Consequently, synaptic proteins 
have the potential to be highly suited as biomarkers for early 
AD diagnosis in addition to monitoring disease progression 
and evaluating novel disease-modifying therapeutics.
Neurogranin (Ng) is a 78-amino acid-long postsynaptic 
protein that plays a critical role in long-term potentiation 
(LTP). LTP is thought to be crucial for the formation of 
long-term memories, through regulating the concentration 
of calmodulin by responding to intracellular calcium lev-
els following neuronal excitation [4, 20, 25, 63]. Ng is able 
to bind to calmodulin via an IQ motif (amino acid 33–46) 
which is well conserved among other calmodulin-binding 
proteins, such as the pre-synaptic protein growth-associated 
protein 43 (GAP-43). In the brain, Ng expression is localized 
to dendritic spines of neurons in the amygdala, hippocam-
pus, cerebral cortex, and other associative cortical areas [10, 
20]. In mice, both Ng mRNA and protein concentrations 
in the hippocampus decrease with age and are related to 
central nervous system (CNS) dysfunction [41]. In addition, 
knockdown models display reduced LTP as well as impaired 
cognition [23] while upregulation improves LTP along with 
cognitive performance [65].
It is well established that cerebrospinal fluid (CSF) Ng 
is increased in sAD compared to healthy controls [17, 24, 
28, 30, 32, 33, 45, 46]. Increased CSF Ng concentrations 
can also be used to distinguish patients with mild cognitive 
impairment (MCI) that will convert to sAD from those that 
remain stable [30, 32, 38, 46]. However, data from brain 
tissue indicate a decrease of Ng concentrations in both the 
frontal cortex [15, 49], parietal cortex [49] and hippocampus 
[15]. We have previously shown that Ng in brain tissue is 
present both as intact full-length protein and as a variety of 
endogenous C-terminal peptides [32]. Therefore, we aimed 
to characterize Ng in brain tissue and to quantify full-length 
Ng and Ng peptides in post-mortem brain tissue of patients 
with sAD, fAD, healthy controls as well as cognitively unaf-
fected amyloid-positive (CU-AP) individuals, which have 
neuropathological changes beyond normal levels for their 
age. We also tested the hypothesis that during the neurode-
generative process of AD, higher amounts of endogenous 
Ng peptides are generated in the brain through processing 
of full-length Ng compared to brains without AD neuro-
pathology. Here, we present results of Ng in post-mortem 
brain tissue from two different cohorts measured by three 
independent methods, showing that full-length Ng in the 
brain has post-translational modifications (PTM) and that 
there is a shift from full-length Ng to peptides in both sAD 
and fAD compared to CU-AP and controls.
Materials and methods
Individuals included in study 1
Post-mortem brain tissue samples from the superior parietal 
gyrus of individuals with sAD (n = 10) and healthy controls 
(n = 10), obtained from the Netherlands Brain Bank, were 
stored at − 80 °C pending biochemical analysis. All sAD 
patients fulfilled Braak stages V or VI and the controls 
fulfilled Braak stages 0 or I in accordance with the Braak 
and Braak criteria [11]. As this material was collected and 
scored before 2012, the 2012 National Institute on Ageing 
(NIA) and the Alzheimer’s Association (AA) guidelines for 
neuropathologic assessment of AD [26] were not used. Con-
trols were assessed by retrospective telephone interviews 
with the next of kin, to assure that they had no cognitive 
symptoms. Demographics of the patients included in study 
1 are shown in Table 1 and full demographics are detailed 
in Online Resource 1.
Individuals included in study 2
Post-mortem brain samples from temporal cortex of patients 
with sAD (n = 9), fAD (n = 10), CU-AP (n = 13) and healthy 
controls (n = 9) were obtained from the Queen Square Brain 
Bank, UCL Institute of Neurology, London, UK. AD patients 
fulfilled the clinical NINCDS criteria for probable AD [39] 
and met the 2012 NIA-AA guidelines for neuropathologic 
assessment of AD [26]. Thal phases were determined as a 
measure of the spread Aβ pathology throughout the brain 
as described [60]. Braak stages were scored according to 
the Braak and Braak criteria [11]. Braak tau neurofibrillary 
tangle staging (PHF-1) and the Consortium to Establish a 
Registry for AD (CERAD) neuritic plaque score (thioflavin 
stain) were used to classify AD neuropathology into four 
groups as described previously (Hyman et al. 2012): no (or 
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negligible) AD neuropathology (0), low level AD (A), inter-
mediate-level AD (B), and high-level AD (C). In addition, an 
ABC score that incorporates histopathologic assessments of 
Aβ deposits (A), staging of neurofibrillary tangles (B) and 
scoring of neuritic plaques (C) was calculated as described 
previously [42]. fAD patients had mutations in either PSEN1 
(n = 8) or APP (n = 2) genes. The PSEN1 mutations included 
R278I, E120K, A434T + T291A, I202F, E184D, S132A, and 
intron 4 and all APP mutations were V717I. Due to the num-
bers of different mutations in the fAD group the cases were 
grouped together for analysis. The cognitively normal status 
of the control cases used in this study was confirmed from 
assessment forms received at brain donation. The assessment 
forms are completed by both the person donating their brain 
and/or by relatives or next of kin. We also have access to all 
the medical records that were summarized by a neurologist. 
The CU-AP patients were cases who had died from acute 
cardiac or malignant disease, without history of dementia, 
or psychiatric or neurological diseases where the autopsy 
examination revealed AD-like pathology beyond what can 
be considered normal for age. A summary of case demo-
graphics of the cases included in study 2 is shown in Table 1, 
with full demographics detailed in Online Resource 1.
Both studies were conducted according to the pro-
visions of the Helsinki Declaration. All subjects gave 
written informed consent for the use of their clinical data 
for research purposes, and the local Ethical Committees at 
the respective university approved each study.
Generation of anti‑Ng antibodies
The monoclonal anti-Ng antibodies Ng2 and Ng3 have 
been described previously [32], while Ng36 was generated 
using the same protocol, but with KLH-conjugated peptide 
Ng63–75 (Caslo ApS Denmark) as immunogen. All of the 
antibodies were purified using a protein G column (GE 
Healthcare).
Homogenization of brain tissue for western blot, 
mass spectrometric analysis and immunoassay
Brain tissue (100 ± 10 mg) (superior parietal gyrus or tempo-
ral cortex) were homogenized on ice in Tris-buffered saline 
(TBS) (1:5 weight:volume ratio) containing complete pro-
tease inhibitor (Roche Diagnostics GmbH, Mannheim, Ger-
many). The homogenized tissue was further diluted in TBS 
(1:5) followed by centrifugation at 31,000g at + 4 °C for 
1 h. The supernatant (TBS fraction) was removed and stored 
at − 80 °C pending analysis. Total protein concentration of 
Table 1  Demographics and clinical characteristics of subjects included in study 1 and 2
Differences between groups in study 1 were assessed using Mann–Whitney U test. Comparisons between groups in study 2 were performed 
using Kruskal–Wallis test with data adjusted for post-mortem delay, followed by pairwise Mann–Whitney U tests if significant. The data are 
presented as median and [interquartile range]
§ sAD vs fAD p = 0.003; *sAD vs CU-AP p = 0.033; †sAD vs controls p = 0.013; ¤fAD vs control p = 0.032; ¤¤fAD vs control p = 0.025; #fAD 
vs CU-AP p < 0.0001; ##fAD vs CU-AP p = 0.029; ###fAD vs CU-AP p = 0.017
sAD Control fAD CU-AP
Study 1 n = 10 n = 10
Gender, n, female/male (% female) 6/4 (60) 6/4 (60)
Age at death 77 [72–79] 72.5 [69.5–80.5]
Post-mortem delay, (h) 5 [4–6] 7 [6–7]
Braak stage 0–I/II–IV/V–VI 0/0/10 10/0/0
Study 2 n = 9 n = 9 n = 10 n = 13
Gender, n, female/male (% female) 3/6 (33) 5/4 (56) 6/4 (60) 9/4 (69)
Age at onset 60 [52–69]§ n/a 43 [36–53] n/a
Duration, (years) 11.5 [10–15] n/a 9 [5–13] n/a
Age at death 72 [66–80]* 82 [70–85]¤ 54 [46–65]# 88 [84–91]
Post-mortem delay, (h) 65 [47–92] 75 [40–86] 38 [26–65]## 78 [39–102]
Brain weight, (g) 1116 [1009–1244]† 1330 [1250–1474] 1108 [880–1320]¤¤ 1264 [1192–1421]
Braak stage 0–I/II–IV/V–VI 0/0/9 7/2/0 0/0/10 1/12/0
Thal stage 0–1/2–4/5–6 0/0/9 8/1/0 0/0/10 1/9/3
CERAD score 0/A/B/C 0/0/0/9 6/2/0/1 0/0/0/10 2/6/5
ABC score, minimum–maximum A3B3C3 A0B0C0–A2B1C1/ 
A1B2C1
A3B3C3 A1B2C2–A3B2C2
Mutation, PSN1/APP 8/2
ELISA, (ng/mg) total protein 253.9 [137-346.2] 398.1 [305.9–631.8] 291.2 [169.9–363.3]### 518.7 [440.1–741.7]
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all homogenized samples was determined using the DC™ 
Protein Assay (Bio-Rad Laboratories) according to the man-
ufacturer’s instructions. The samples were diluted in PBS 
(1:40) prior to immunoprecipitation.
Hybrid immunoaffinity–mass spectrometry
4 µg of the anti-Ng antibodies Ng2 and Ng3 were sepa-
rately added to 25 μL M-280 Dynabeads (Sheep anti-mouse 
IgG, Invitrogen) according to the manufacturer’s product 
description and cross-linked as previously described [12]. 
Ng2- and Ng3-coated beads were used for immunoprecipi-
tation of brain extracts to which Tween 20 (final concentra-
tion 0.025%) was added and incubated. Beads and samples 
were transferred to a KingFisher magnetic particle proces-
sor (polypropylene tubes, Thermo Scientific, Waltham, MA, 
USA) for automatic washing and elution of full-length and 
Ng peptides. Eluted Ng was collected and dried in a vacuum 
centrifuge and re-dissolved in 5 μL 0.1% formic acid (FA) 
in 20% acetonitrile (ACN) and subsequently analyzed using 
a Bruker Daltonics UltraFleXtreme matrix assisted laser 
desorption/ionization time-of-flight/time-of-flight (MALDI 
TOF/TOF) mass spectrometer (Bruker Daltonics, Bremen, 
Germany) or high-resolution tandem mass spectrometry 
(MS/MS) using a Dionex Ultimate 3000 nanoflow liquid 
chromatography (LC) system (Thermo Fisher Scientific). A 
detailed description about LC–MS/MS and database searches 
that were performed can be found in Online Resource 2. All 
solvents used were of HPLC grade. In both studies in which 
MALDI TOF/TOF MS was used, the custom Ng peptide 
RKKIKSGERGRKGPGPGGPGGAGVARG GAG GGP (cor-
responding to Ng43–75), with all glycines fully labeled with 
13C (theoretical molecular mass: 3011 Da; CASLO, Lyngby, 
Denmark), was added to the tissue homogenate during sam-
ple preparation and was used as an internal standard. Samples 
were analyzed blinded (that is, without knowledge of clinical 
diagnosis). All calculated concentrations were normalized to 
total protein concentration of the sample.
Reduction and alkylation of full‑length neurogranin
Full-length Ng from brain tissue was first purified according 
to the hybrid immunoaffinity–mass spectrometry (HI–MS) 
procedure. After vacuum centrifugation, the samples were 
dissolved in 5 μL 20% ACN and vortexed for 1 h. Thereaf-
ter 15 µL 50 mM  NH4HCO3 was added and samples were 
vortexed. Then 20 μL 10 mM dithiothreitol (DTT) in 50 mM 
 NH4HCO3 was added to the samples followed by a 3-min 
incubation at + 90 °C. The samples were allowed to cool 
to room temperature for 30 min after which 40 μL 10 mM 
iodoacetamide in 50 mM  NH4HCO3 was added. Samples 
were then incubated at room temperature in the dark for 
30 min after which they were dried in a vacuum centrifuge 
and stored at − 80 °C pending MS analysis. Negative con-
trol samples were only incubated 3 min at 90 °C without 
the addition of DTT prior to drying in a vacuum centrifuge.
Western blot
1 µg of total protein was mixed with XT sample buffer (Bio-
Rad Laboratories) and XT reducing agent (Bio-Rad Labora-
tories) before boiling 5 min at 95 °C. Samples and full-length 
recombinant calibrator Ng–Myc–DKK fusion protein (Ori-
gene, product no TP301209) ranging from 1.56 to 25 ng were 
electrophoresed on 12% Criterion XT Bis–Tris Gel using the 
Criterion cell tank (Bio-Rad Laboratories). The proteins were 
transferred to 0.2 µm nitrocellulose membrane (Amersham), 
using the semi-dry blotting technique. Blocking was per-
formed for 1 h at room temperature using 5% blotting-grade 
blocker (Bio-Rad Laboratories) in phosphate-buffered saline 
(0.01 M phosphate buffer, 0.14 M NaCl, pH 7.4; PBS) con-
taining Tween 20 (Bio-Rad Laboratories, final concentration 
0.05%; PBS-Tween). Incubations with the monoclonal Ng36 
diluted 1:1250 in 1% blotting-grade blocker in PBS-Tween or 
no primary antibody (negative control) was performed over-
night at + 4 °C. The membranes were washed for 3 × 10 min 
in PBS-Tween and then incubated for 1 h at room tempera-
ture with goat anti-mouse IgG (H + L) poly-HRP second-
ary antibody HRP (0.5 mg/mL) (Thermo Fisher Scientific) 
diluted 1:15,000 in PBS-Tween containing 1% bovine serum 
albumin (BSA). Following 3 × 10 min washes in PBS-Tween, 
the membranes were developed for 2 min with ECL Select™ 
Western Blotting Detection Reagent (GE Healthcare) accord-
ing to the manufacturer’s instructions. The emitted signal 
was detected by a Fujifilm LAS-3000 System (FUJIFILM 
Corporation) and protein bands were quantified using ImageJ 
software version 1.51j8 (Rasband, WS, ImageJ; National 
Institutes of Health, Bethesda, MD, http://rsb.info.nih.gov/ij). 
 SOFTmax® Pro 4.0 (Molecular Devices Corporation, Sun-
nyvale, CA, USA) and a fitted four-parameter logistic model 
calibration curve were used to quantify Ng concentration of 
samples. Samples that were below the lowest point of the 
standard curve but still visible were given a value of half the 
lowest concentration, i.e., 0.78 ng. A standard curve, negative 
controls, quality control sample of brain tissue homogenate 
and molecular size marker SeeBlue Plus2 Pre-stained protein 
standard (Thermo Fisher Scientific) was included on all gels.
Sandwich ELISA method of Ng
Ng36 was used as a capturing antibody and was coated 
on Nunc maxisorp 96-well microtiter plates at a final 
concentration of 0.5 μg/mL (100 µL/well) in  NH4HCO3 
buffer, pH 9.6, overnight at + 4 °C. After washing with 
PBS-Tween 4×350  µL, the remaining protein binding 
sites were blocked with 1% BSA in PBS-Tween for 1 h at 
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room temperature (250 μL/well). Thereafter, plates were 
washed with PBS-Tween 4×350 µL. Full-length GST-
tagged recombinant Ng calibrators with concentrations 
ranging between 7 and 940 pg/mL, blanks and TBS brain 
samples (diluted 1:10,000, 100 μL/well) were incubated 
in duplicate for 3 h at room temperature, 350 rpm, fol-
lowed by washing with 4 × 350 µL PBS-Tween. Detector 
antibody, biotinylated Ng2 final concentration 0.5 μg/mL 
(100 µL/well) in 1% BSA PBS-Tween, was added followed 
by incubation for 1 h at room temperature and washing 
with 4×350 µL PBS-Tween. Enhanced streptavidin-HRP 
(KemEnTech) was diluted according to the manufacturer’s 
instructions and added (100 µL/well) and incubated 30 min 
at room temperature. After washing with 4×350 µL PBS-
Tween, TMB substrate (BioRad Laboratories, 100 µL/
well) was added to produce the color reaction. After 
20 min in darkness, the reaction was stopped by addition 
of 100 μL of 0.2 M  H2SO4, and following 1 min incuba-
tion at room temperature, 450 rpm, the absorbance was 
measured at 450 nm (reference wavelength 650 nm) using 
an ELISA plate reader (Sunrise, Tecan Trading AG, Swit-
zerland). A fitted four-parameter logistic model was used 
as the calibration curve and the blank was included as zero 
concentration of Ng (SoftMax Pro v. 4.0).
Statistical analysis
In the first study cohort containing individuals with sAD 
and controls, we analyzed differences in total full-length 
Ng, meaning the sum of all Ng1–78 with various modifica-
tions and the peptide-to-total full-length Ng ratio of all Ng 
peptides identified by HI–MS. The data in the second study 
cohort, containing individuals with sAD, fAD, CU-AP, and 
controls, were analyzed in the same way as for the first study. 
Because there were more than two groups in this cohort, we 
first performed the non-parametric Kruskal–Wallis test for 
differences between groups, followed by post hoc pairwise 
Mann–Whitney U tests for individual group differences if 
the Kruskal–Wallis test was significant. All Ng measures 
in this study were first adjusted for post-mortem delay and 
age. Additionally, we analyzed the association between 
Ng and Aβ and tau pathology in the second cohort by cal-
culating the Spearman correlation between HI–MS/WB/
ELISA values and both Braak and Thal staging. We tested 
for group differences in Ng values between Braak stages 
0–I, II–IV, V–VI, and separately between Thal scores 0–1, 
2–3, 4–5, and again separately between CERAD scores 0, 
A, B, C—each using the Kruskal–Wallis test with post hoc 
pairwise Mann–Whitney U tests if the main effect was sig-
nificance. All tests were two-sided with a significance level 
set to p < 0.05. p values for each family of comparisons were 
adjusted for multiple comparisons using Holm’s method to 
control the family-wise error rate. Statistical analysis was 
performed using GraphPad Prism 7 (GraphPad Software, 
La Jolla, USA) and the R programming language (v. 3.4.3).
Results
Neurogranin is present as both endogenous 
peptides and modified full‑length form
Brain Ng was characterized using HI–MS and we found 
that Ng is present as a variety of short endogenous peptides, 
all located in the C-terminal part of the protein. In total, 15 
peptides were repeatedly detected using MALDI TOF/TOF 
(Fig. 1) and an additional 24 peptides were identified by high-
resolution mass spectrometry (Fig. 2 and Online Resource 
3). By using a combination of HI–MS and high-resolution 
MS/MS we found that several post-translational modifica-
tions (PTMs) were present on full-length Ng. We were able 
to identify Ng1–78 with acetylation and a disulfide bridge, 
Ng1–78 with acetylation, disulfide bridge and cysteinyl, and 
Ng1–78 with acetylation, disulfide bridge and a glutathione 
(GSH) (Fig. 3a, c). In addition, all variants could also include 
one or two oxidations. A detailed data analysis showed that 
the disulfide bridge was located either between cysteine (C) 3 
and C4 or between C4 and C9. GSH and cysteinyl may then 
be attached on either C9 or C3 depending on the location of 
the disulfide bridge. The acetylation was always attached to 
the protein N-terminal methionine M1 (Fig. 3b and Online 
Resource 4) and the oxidations to M1 or M41. Full-length 
Ng with the different sets of PTMs also had different reten-
tion time profiles (Fig. 3c). When reducing Ng with DTT the 
peaks representing Ng1–78 containing GSH or cysteinyl were 
greatly reduced (Fig. 3d, e). These results were confirmed with 
LC–MS/MS.  
The peptide‑to‑full‑length neurogranin ratios are 
decreased in superior parietal gyrus of sporadic 
Alzheimer’s disease
In study 1, full-length Ng as well as 14 endogenous peptides, 
which were detected in all samples, was quantified in the 
superior parietal gyrus of individuals with sAD and healthy 
age-matched controls. After analyzing the ratio between each 
of the peptides and the sum of Ng1–78 with the three sets of 
PTMs, hereby referred to as total full-length Ng, we found 
that 8 peptide-to-total full-length Ng ratios were significantly 
increased in sAD compared to controls (p < 0.05 for all ratios) 
(Fig. 4 and Online Resource 5), thus indicating increased con-
centrations of these peptides compared to total full-length Ng.
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Neurogranin peptides are increased and full‑length 
neurogranin is decreased in sporadic and familial 
Alzheimer’s disease
To validate these findings, we first used HI–MS in a sec-
ond study with temporal cortex from individuals with sAD, 
fAD, CU-AP and controls. In total ten endogenous peptides, 
of which all except one were the same as in study 1, were 
quantified in a majority of the samples in addition to full-
length Ng. There were significant differences across groups 
in peptide-to-total full-length Ng ratios for nine of the ten 
peptides detected in this study. One of the strongest differ-
ences was found in peptide-to-total full-length Ng ratio of 
Ng53–78 (p = 0.0008). For this peptide (Fig. 5a), a post hoc 
test revealed that peptide-to-total full-length Ng ratio was 
significantly reduced in sAD and fAD compared to controls 
(p = 0.004 for sAD; p = 0.0005 for fAD), and compared to 
CU-AP (p = 0.007 for sAD; p = 0.002 for fAD). Results for 
the other peptides are summarized in Online Resource 6 
and 7.
Furthermore, there was a significant difference in total 
full-length Ng concentrations measured by HI–MS across 
groups (p = 0.0008). Post hoc analysis showed that total 
full-length Ng levels were significantly reduced in indi-
viduals with fAD compared to sAD (p = 0.03), CU-AP 
(p = 0.0003), and controls (p = 0.01) (Fig. 5b). There was 
also a trend, although not statistically significant, towards 
reduced total full-length Ng in sAD compared to controls 
and CU-AP.
In addition to HI–MS, the second cohort was also ana-
lyzed by WB (Fig. 5c) and ELISA. To ensure that the mono-
clonal antibody Ng36, which was used both in the ELISA 
and WB, was specific for Ng it was first characterized by 
HI–MS. Human brain tissue was analyzed by HI–MS and 
we were able to confirm that Ng36 is specific for Ng and 
detects the same peptides and full-length Ng as Ng2 and 
Ng3 (Online Resource 8).
For WB, there were significant differences across groups 
(p = 0.003), with again significantly lower concentrations 
in fAD compared to CU-AP (p = 0.008), and controls 
(p = 0.0002) (Fig. 5d). ELISA analysis also showed sig-
nificant differences across groups (p = 0.008), with signifi-
cantly lower concentrations in fAD compared to CU-AP 
(p = 0.035), and controls (p = 0.003), and significantly lower 
concentrations in sAD compared to CU-AP (p = 0.017) 
(Fig. 5e).
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Fig. 1  Hybrid immunoaffinity–mass spectrometric characterization 
of endogenous neurogranin peptides in human brain tissue. Several 
short endogenous C-terminal peptides were repeatedly detected in 
human parietal cortex using the monoclonal antibodies Ng2 + Ng3 
and MALDI TOF/TOF. Ng43–75* represents internal standard fully 
labeled with 13C
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Neurogranin levels differ between degrees 
of neuropathological changes
After grouping all individuals from study 2, independent 
of diagnosis, by Braak stages 0–I (no or little tau pathol-
ogy), II–IV (moderate tau pathology), and V–VI (high-level 
tau pathology), we found a significant group difference in 
total full-length Ng, Ng measured by WB, Ng measured 
by ELISA, and peptide-to-total full-length Ng ratios of all 
peptides (all p < 0.02). Post hoc tests revealed that Ng lev-
els increased with increasing Braak pathology for each of 
the tested measurements, results are summarized in Online 
Resource 9. After grouping individuals independent of 
diagnosis by Thal stages 0–1, 2–3, and 4–5, we found a 
significance group difference only in the peptide-to-total 
full-length Ng ratio of Ng53-78 (p = 0.03). A post hoc test 
showed that Ng values in Thal stages 0–1 were significantly 
lower than in stages 2–3 (p = 0.003) and nearly significantly 
lower than in stages 4–5 (p = 0.052). Results are summarized 
in Online Resource 9. Finally, after grouping individuals 
independent of diagnosis by CERAD score 0, A, B, and 
C, we found a significant group difference in total full-
length Ng, Ng measured by WB, Ng measured by ELISA, 
and peptide-to-total full-length Ng ratios of all peptides (all 
p < 0.03). Again, post hoc tests showed increasing peptide-
to-total full-length Ng ratios with increasing CERAD scor-
ing. Results are summarized in Online Resource 9.
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Fig. 2  Summary of all identified neurogranin peptides in human brain tissue. In total, 39 endogenous Ng peptides were identified using a combi-
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Fig. 3  Hybrid immunoaffinity–mass spectrometric characterization 
of full-length neurogranin in human brain tissue. A cluster of peaks 
representing full-length Ng with different sets PTMs (a). Amino 
acid sequence of Ng1–78 with acetyl, disulfide bridge and GSH 
with the positions of PTMs and b- and y-ions identified from a sin-
gle MS/MS acquisition indicated (b). Full-length Ng with different 
PTM arrangements had different retention time during high-reso-
lution LC–MS/MS analysis (c). Expansion of the m/z range around 
m/z 7500 in a MALDI mass spectrum from human brain tissue after 
heat-treatment without reduction with DTT showed a cluster of 
peaks representing Ng1–78. The rightmost peak represents Ng1–
78 + acetyl + GSH + disulfide bridge (d). A similar mass spectrum 
from human brain tissue after heat-treatment and reduction with DTT 
showed another cluster of peaks representing full-length Ng. Here 
the peak representing Ng1–78 + acetyl + GSH + disulfide bridge was 
greatly reduced (e)
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Fig. 4  Scatterplots displaying the result from hybrid-immunoaffinity 
mass spectrometry in study 1. Scatterplots displaying the peptide-
to-total full-length Ng ratio ×1000 for Ng53–75  (a), Ng53–78  (b), 
Ng51–78 (c), Ng48–76 (d), Ng48–78 (e), Ng44–76 (f), Ng42–78 (g) 
and Ng41–78  (h). The data presented are median and interquartile 
ranges. Differences between groups were assessed using Mann–Whit-
ney U test
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Discussion
In 2015 we used HI–MS to show that several endogenous 
Ng peptides are present in both CSF and brain tissue and 
Ng48–76 was increased in sAD CSF [32] Therefore we 
aimed to investigate Ng in brain tissue in more detail by 
combining HI–MS, ELISA and WB analysis to find an 
explanation to why Ng seems to be decreased in sAD brains, 
as shown previously [15, 49], and increased in CSF from 
sAD patients. In the current study, we have performed an 
extensive characterization of Ng in post-mortem human 
brain tissue and quantified and compared the expression pat-
tern of brain Ng in relation to AD pathology in sAD, fAD, 
and CU-AP to controls.
HI–MS combined with high-resolution MS/MS showed 
that full-length Ng is post-translationally modified by the 
addition of an N-terminal acetyl group, disulfide bridge (at 
C3–C4 or C4–C9), cysteinyl (at C3 or C9), and GSH (at C3 
or C9), but does not exclude the possibility of other com-
binations of the reported variants, or different PTMs being 
present on full-length or nearly full-length Ng. Support of 
the reported PTMs include MS/MS data of the individual 
Fig. 5  Scatterplots and western 
blot analysis of study 2. Scat-
terplot displaying the peptide-
to-total full-length Ng ratio 
×1000 for Ng53–78. #Sample 
ratio is > 150,000 (a). Scatter-
plot displaying total full-length 
Ng concentration measured 
by HI–MS (b). WB using the 
monoclonal antibody Ng36 (left 
blot) or no primary antibody 
(right blot). Briefly, samples 
were relatively quantified in WB 
by including a standard curve 
of recombinant Ng-MYC-DDK 
protein on each gel. Lanes 1–5: 
standard curve of Ng–Myc–
DKK fusion protein ranging 
from 25 to 1.56 ng. Lane 6: 
quality control (QC) brain tis-
sue sample. Lanes 7–9: patient 
samples from study 2. Lane 
10: QC tissue sample. Lane 11: 
Ng–Myc–DKK fusion protein 
12.5 ng. Lanes 10 and 11 were 
used as negative controls (c). 
Scatterplot displaying results 
from WB analysis. The y-axis 
displays the Ng concentration 
in ng/mg total protein in each 
sample (d). Scatterplot display-
ing ELISA results. The y-axis 
displays the Ng concentration in 
ng/mg total protein in each sam-
ple (e). The data presented are 
median and interquartile ranges. 
Comparisons between groups 
were performed using Kruskal–
Wallis test with data adjusted 
for post-mortem delay, followed 
by pairwise Mann–Whitney U 
tests if significant
 Acta Neuropathologica
1 3
protein species and that the protein containing the differ-
ent PTM combinations had different retention times. It has 
previously been shown that reducing samples with DTT 
prevents GSH adducts from forming [2]. The fact that the 
peak representing Ng1–78 with disulfide bridge and GSH 
was greatly diminished when reducing the sample with DTT 
add additional proof that GSH is present on Ng at a cysteine. 
Our results show that a substantial portion of full-length Ng 
has GSH as a PTM. GSH, which is the most abundant anti-
oxidant in the brain, plays a significant role in counteracting 
oxidative stress by reacting with free radicals [43]. Proteins 
that are sensitive to redox might be protected from OS by 
glutathionylation and several proteins in AD brain, includ-
ing p53 which can initiate apoptosis, have been identified 
as having a GSH PTM [19]. Loss of synapses is considered 
the mechanism that precedes neuronal loss and correlates 
best with cognitive impairment in AD [18, 51, 54, 57]. Both 
in vivo and in vitro studies suggest a direct relationship 
between synaptic dysfunction and oxidative stress in AD 
[14, 29, 35, 48], thus indicating that a GSH PTM on intact 
Ng might be a means of protection against oxidative stress 
to preserve protein function.
We were able to quantify several Ng peptides in both 
studies, although some of them differed between the two 
materials. This was most likely because the tissues used in 
the studies were from different regions. Using HI–MS we 
were able to quantify several peptides as well as full-length 
Ng with PTMs separately. In WB, the peptides were prob-
ably too small and exited the gel meaning that this method 
mainly quantifies full-length, or nearly full-length, Ng. In 
contrast, the ELISA most likely detects a mixture of both 
full-length Ng and many different peptides.
AD pathology (plaques and tangles) are common in older 
non-demented individuals, with an estimated 30–40% of 
cognitively intact elderly classed as positive upon autopsy 
[7, 31, 47]. Recently, new guidelines for diagnosis of AD 
based on biomarkers reflecting the key pathologies were 
published by the NIA and the AA to update and unify the 
2011 NIA/AA guidelines according to the current under-
standing of the disease [40]. In the new 2018 NIA/AA 
guidelines for researchers, a diagnosis of AD is defined by 
its underlying pathologic processes that can be documented 
by post-mortem examination or followed in vivo using imag-
ing or fluid biomarkers and not by symptoms or signs, such 
as cognitive decline, which are rather clinical consequences 
of the resulting neurodegeneration [27]. According to these 
criteria, the CU-AP would be classified as preclinical Alz-
heimer’s pathologic change in the Alzheimer’s continuum. 
In the present study, the sAD and CU-AP groups were dif-
ferent from each other with sAD having significantly higher 
concentrations for many of the measured Ng peptides 
compared to full-length Ng than CU-AP. In addition, the 
sAD and fAD subjects appear to be subjected to a similar 
processing of full-length Ng into peptides, whereas for con-
trols and CU-AP the degradation is not so evident. Most 
importantly, the CU-AP individuals do not have any signs 
of lowered cognitive function despite mild to moderate neu-
ropathological changes. Thus, grouping the AD and CU-AP 
subjects together would not be appropriate since CU-AP do 
not demonstrate an increase of Ng peptides and a decrease of 
full-length Ng, which might reflect degenerating synapses. 
In addition, differences between CU-AP and sAD have been 
described previously. Post-mortem brain tissue from half of 
the CU-AP individuals included in study 2 were previously 
analyzed and shown to contain less N-terminally truncated 
and pyroglutamate-modified Aβ peptides compared to sAD 
cases [44]. This would suggest that these individuals indeed 
are different from patients with sAD, and most likely also 
fAD, even though they share neuropathological changes in 
the brain.
Even though most CU-AP individuals have tau and amy-
loid pathology above what can be expected for their age they 
somehow still managed to remain cognitively intact. There is 
a possibility that these subjects were able to compensate for 
the synaptic damage and loss induced by these pathologies, 
thus keeping their full-length Ng levels in the same range as 
controls. Mouse models have shown that upregulation of Ng 
not only improves LTP but also enhances cognitive perfor-
mance [65], hence suggesting that an increase in Ng might 
be beneficial for cognition in humans as well. As there was a 
trend towards increased full-length Ng in CU-AP compared 
to controls as measured by WB, it is possible that the CU-AP 
individuals are able to respond to the pathological changes 
and counteract or compensate for the cognitive decline these 
would otherwise cause, perhaps by increasing the numbers 
of synapses or simply producing more full-length Ng thus 
providing them with the means of a cognitive reserve.
As peptide-to-total full-length Ng ratios were increased 
in sAD compared to controls in both studies, and in the sec-
ond study also for sAD compared to CU-AP and in fAD 
compared to both controls and CU-AP, there seems to be 
a shift from intact protein to endogenous peptides in both 
forms of AD. WB mainly detects full-length, or nearly full-
length, Ng since the peptides appears to be too small and 
most likely exit the gel. Consequently, WB results also sup-
port the hypothesis of decreased full-length Ng as fAD had 
significantly lower concentrations compared to CU-AP as 
well as a trend towards lower levels compared to sAD. Simi-
larly, the sAD group also had an apparent trend of lower con-
centrations compared to both controls and CU-AP in both 
WB and ELISA. In contrast to WB, the ELISA most likely 
detects a mixture of both full-length Ng and many different 
peptides as both Ng2 and Ng36 are able to bind Ng in the 
form of both peptides and full-length protein. This might 
in turn explain why the group separation was less evident 
compared to WB. However, HI–MS analysis showed that 
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even though peptide concentrations are increased in both 
sAD and fAD there is still very high levels of full-length 
Ng left, which is most likely why the ELISA results still are 
more similar to WB than HI–MS. Taken together, this shows 
that full-length Ng most likely is degraded into at least some 
of the peptides measured by HI–MS. The results from the 
ELISA are very similar to WB with significantly lower con-
centrations in fAD compared to CU-AP and, although not 
reaching statistical significance, a trend towards lower con-
centrations in AD compared to both controls and CU-AP 
and as well as when comparing fAD with controls. Thus, the 
three methods indicate the same conclusion; that full-length 
Ng is decreased in both sAD and fAD.
Since we saw clear differences in the peptide-to-total full-
length Ng ratios between the two AD groups compared to 
controls and CU-AP for many of the detected peptides, it 
might be of potential interest to develop an assay capable 
of measuring these two pools of Ng in the future. Currently, 
full-length and peptide Ng are measured by HI–MS, which 
is both quite time-consuming and inefficient compared to an 
immunoassay. The ELISA presented here most likely quan-
tifies both full-length and peptide Ng, and the separation 
between the groups is not as good compared to peptide-to-
total full-length Ng ratio. In theory, it might be possible to 
develop two assays that quantify peptide and full-length Ng, 
respectively. Using a similar approach, the Aβ42/40 ratio 
has successfully been shown to increase diagnostic accuracy 
[22, 34, 56] and have diagnostic value in clinical settings 
[21], as well as circumventing the issue of high- and low-
producers [62].
It is well established that neuronal and synaptic loss 
are early and central events in AD pathology [18, 37, 52] 
and that synaptic density is reduced by more than 30% 
even in the earliest stages of AD [16]. In fact, both cogni-
tive decline and disease progression can be monitored by 
measuring synaptic loss as it appears to be more closely 
correlated with cognitive deficits than plaque and tangle 
load [37, 52, 58]. In rodents, Ng mRNA and protein con-
centrations in the hippocampus decrease with age and are 
related to CNS dysfunction [41] and knockdown models 
display both impaired cognition and reduced LTP [23]. In 
humans, it has been shown that high CSF Ng was posi-
tively associated with increased rate of hippocampal atro-
phy [46] as well as other parts of the brain [59]. Taken 
together, it seems probable that the proteolytic processing 
of full-length Ng into peptides during neurodegeneration, 
visualized here as increased peptide-to-total full-length 
Ng concentrations in sAD and fAD, may be triggered by 
synaptic degeneration and neuronal loss. According to the 
literature, at present day Ng does not seem to be a con-
firmed substrate for any enzymes. However, recently we 
showed that that calpain-1 and prolyl endopeptidase are 
capable of cleaving full-length Ng within the IQ domain 
and near the C-terminal end, respectively in vitro resulting 
in several of the endogenous peptides we have found in 
brain tissue and CSF [5]. Notably, several of the endog-
enous peptides identified from brain tissue start just after 
the C-terminal end of the IQ motif. Since the IQ motif 
is needed for calmodulin-binding [3, 50], the cleavage 
would most likely inhibit Ng binding to calmodulin, as 
it does for GAP-43 [64], which in turn would affect LTP 
and therefore formation of long-term memory excitation 
[4, 20, 25, 63]. Future studies on the role of this enzymatic 
activity would be of interest to further understand the link 
between neurodegeneration and enzymatic cleavage of Ng 
into the observed peptides as they are not all accounted for 
by cleavage of calpain-1 and prolyl endopeptidase alone.
We previously showed a strong association between CSF 
Ng and degree of AD neuropathology independent of diag-
nosis in a study containing several neurodegenerative dis-
eases [45]. In the present study, we confirmed the CSF study 
as brain Ng levels were increasing with both Braak stage, 
CERAD score and to some extent Thal phase, meaning that 
Ng is associated with both Aβ and tau pathology. However, 
CERAD scores showed a much stronger association with Ng 
levels compared to Thal phases. This may be due to the fact 
that Thal phases are a measure of how far the Aβ pathology 
has spread around the brain, regardless of how much Aβ is 
present, whereas the CERAD score is a measure of the quan-
tity of Aβ plaques found in the cortical areas. For example, 
to reach a Thal phase 1, Aβ plaques must be present in any 
cortical region, but this gives no information at all about the 
actual number of plaques present. In conclusion, our data 
shows that Ng is much more closely associated with plaque 
load compared to the spreading of Aβ pathology. This is in 
line with previous findings that CSF Ng is positively cor-
related with CERAD scores in autopsy-confirmed cases of 
AD [45]. Evaluating the levels of Ng in CSF from patients 
with primary tauopathies, without amyloid plaque pathol-
ogy, might give us further insight into the association with 
tau as previous studies on CSF Ng have shown strong cor-
relations with CSF tau [17, 24, 30, 33, 38, 61].
The major limitations of this paper are the small sample 
sizes in both studies and significant age differences between 
the groups in study 2. The sample sizes are limited since 
high-quality post-mortem tissue meeting the neuropatho-
logical demands of the groups included in these studies is 
very restricted. Regarding age differences in study 2, fAD 
was significantly younger than both controls and CU-AP, 
and sAD was younger than CU-AP. However, as sAD and 
controls were age-matched in both studies, and there was no 
significant difference in age between controls and CU-AP, 
it is unlikely that the reported differences in Ng concentra-
tions are due to the age differences. Since this study was 
performed on post-mortem tissue, it was difficult to ensure 
age matching between AD and control groups of the two 
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separate studies as well as all four groups included in the 
second study, especially considering the fAD group will be 
younger than the sAD group. To compensate for any impact 
the age differences may have on the results, all data was 
adjusted for age. Post-mortem delay was significantly shorter 
in fAD compared to CU-AP therefore statistical analysis 
were adjusted for this.
We have performed an extensive characterization of 
the postsynaptic protein Ng in human brain tissue. Using 
HI–MS it was shown that Ng is present as a variety of 
endogenous peptides as well as post-translationally modi-
fied full-length protein. The identified PTMs were acetyl, 
disulfide bridge, cysteinyl, and GSH modifications, as well 
as oxidation. The most important discovery was that sAD 
and fAD had increased concentrations of endogenous pep-
tides as well as a decrease in full-length Ng indicating a 
shift from intact protein towards peptides. This shift was not 
present in healthy controls or CU-AP individuals, of which 
the latter have both plaque and tangle pathology but no cog-
nitive impairment, hence indicating that Ng is a biomarker 
for AD-related synaptic degeneration that leads to cognitive 
decline. This was also supported by the finding that Ng lev-
els were strongly associated with degree of neuropathologi-
cal changes, as measured by Braak stage, Thal phases, and 
CERAD scores, independent of diagnosis.
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